Mannkind (MNKD) Net Income towards Common Stockholders Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Mannkind | 1.09 Bn | 956.66 Mn | 82.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.17% |
| Dec 31, 2025 | 4.58% |
| Sep 30, 2025 | 22.06% |
| Jun 30, 2025 | 15.61% |
| Mar 31, 2025 | 27.82% |
| Dec 31, 2024 | 20.62% |
| Sep 30, 2024 | 25.50% |
| Jun 30, 2024 | 30.46% |
| Mar 31, 2024 | 22.10% |
| Dec 31, 2023 | 17.03% |
| Sep 30, 2023 | 16.52% |
| Jun 30, 2023 | 25.33% |
| Mar 31, 2023 | 20.26% |
| Dec 31, 2022 | -17.31% |
| Sep 30, 2022 | 15.19% |
| Jun 30, 2022 | 3.86% |
| Mar 31, 2022 | -9.75% |
| Dec 31, 2021 | -20.30% |
| Sep 30, 2021 | -15.27% |
| Jun 30, 2021 | -3.47% |
| Mar 31, 2021 | 12.28% |
| Dec 31, 2020 | -18.39% |
| Sep 30, 2020 | 18.79% |
| Jun 30, 2020 | 18.73% |
| Mar 31, 2020 | 21.19% |
| Dec 31, 2019 | 18.13% |
| Sep 30, 2019 | 22.26% |
| Jun 30, 2019 | 29.94% |
| Mar 31, 2019 | 22.15% |
| Dec 31, 2018 | 33.02% |
| Sep 30, 2018 | 13.81% |
| Jun 30, 2018 | 13.24% |
| Mar 31, 2018 | 5.80% |
| Dec 31, 2017 | 28.93% |
| Sep 30, 2017 | 5.15% |
| Jun 30, 2017 | 0.69% |
| Mar 31, 2017 | 15.62% |
| Dec 31, 2016 | 28.35% |
| Sep 30, 2016 | 39.56% |
| Jun 30, 2016 | 7.60% |
| Mar 31, 2016 | 9.74% |
| Dec 31, 2015 | 32.70% |
| Sep 30, 2015 | 6.80% |
| Jun 30, 2015 | 7.31% |